NASDAQ · EXEL

Exelixis Inc.

$55.81 +$0.44 (+0.79%) 1D After hours
Charting by TradingView

Key Metrics

$13.92B
Market cap
16.70×
P/E · TTM
$2.38B
Revenue · TTM
$833.42M
Net income
EPS · TTM $2.89
Dividend yield —
Free cash flow $917.69M
Beta · 1Y 0.57
EBITDA · TTM $965.33M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 6
    The stock moved +9.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$13.92B
Enterprise value—
Shares outstanding251.4M
52-wk range$33.76 – $57.57
Avg volume · 20D2.4M
Net cash —
Book value / share$6.72
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Exelixis Inc.
IPO dateApr 11, 2000
Employees1077

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E16.70
P/S5.86
P/FCF15.17
EV/EBITDA—
EV/Sales—
Graham №$20.91

Profitability

Gross —
Operating 39.4%
Net 35.1%
FCF 38.6%
ROE / ROIC 39.9% · —

Financial Health

Current ratio3.26
Quick ratio3.19
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$837.66M

Cash Flow · TTM

Operating CF $924.68M
Capex −$6.99M
Free cash flow $917.69M
Buybacks $1.09B
Dividends paid —
Shareholder yield 7.9%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

15.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$20.91 vs $55.81
Trades 2.7× above classic defensive value — priced for growth
Fundamentals through 2026-04-03 · computed by TickerWolf from SEC filings